Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06541574 · ClinicalTrials.gov registry record · Phase 2
Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
A Phase 2 study of Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy, sponsored by Cincinnati Eye Institute, Southwest Ohio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 860
- Enrollment target
- 1
- Study location
NCT06541574 is a Phase 2 study of Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy that is actively recruiting participants, run by Cincinnati Eye Institute, Southwest Ohio. The registered enrollment target is 860 participants, above the 99-participant average among 3 other Rhegmatogenous Retinal Detachment trials with a reported enrollment target (769% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06541574, a Phase 2 study of Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy, is actively recruiting participants, sponsored by Cincinnati Eye Institute, Southwest Ohio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 860 participants
- Enrollment target
- 1
- Study location
Study Summary
I. Title Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial * Today's Date: September 18, 2023 II. Principal Investigator * Principal Investigator: Christopher D. Riemann, M.D. (Cincinnati Eye Institute) * Email: criemann@cvphealth.com, Phone: 513-708-1979 V. Research Summary Purpose: To evaluate methotrexate for the prevention of PVR after primary rhegmatogenous retinal detachment repair. Methods: Inclusion Criteria: • Any adult patient, age ≥18 years-old, undergoing primary rhegmatogenous retinal detachment surgery with pars plana vitrectomy at the Cincinnati Eye Institute in Blue Ash, Ohio who is able to give informed consent. Exclusion Criteria: * Age \<18 years old * Pregnant patients or patients of child bearing potential unwilling to utilize long term contraception for the 12-week period spanning vitrectomy surgery for retinal detachment repair up until the 3 month postoperative visit. * History of endophthalmitis, ruptured globe or significant trauma in the affected eye * Chronic retinal detachment (symptoms greater than or equal to six weeks) * Any previous previous retinal detachment repair with pars plana vitrectomy, or scleral buckling surgery. Patients having undergone previous pneumatic retinopexy will not be excluded. * Presence of Grade C PVR: full thickness retinal folds or subretinal bands * Patients with contraindications to methotrexate, including breastfeeding, pregnancy, attempting to conceive a child or any known hypersensitivity or intolerance to methotrexate * Patients with diminished mental capacity precluding their ability to give informed consent. Study Design and Randomization This prospective double masked trial will randomize patients into four groups in a 1:1:1:1 fashion. All attending surgeons and patients will be masked to group randomization. Randomization into four groups will occur on the day of surgery by the Cincinnati Eye Institute's
Conditions Studied
Interventions
- DRUG Methotrexate Injection
- DRUG Methotrexate Infusion
- DRUG Sham Injection
Study Locations (1)
Ohio
- Cincinnati Eye Institute - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 860 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06541574
The ClinicalTrials.gov registry entry for NCT06541574 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 860 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 99-participant average among 3 other Rhegmatogenous Retinal Detachment trials with a reported enrollment target (769% higher). The listed sponsor is Cincinnati Eye Institute, Southwest Ohio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Rhegmatogenous Retinal Detachment appearing as the primary indexed condition, and to 3 interventions - of which Methotrexate Injection is the first listed.
NCT06541574 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06541574 about?
NCT06541574 is a clinical study titled "Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial". I. Title Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial * Today's Date: September 18, 2023 II. Principal Investigator * Principal Investigator: Christopher D. Riemann, M.D. (Cincinnati Eye Institute) * Email: criemann@...
What is the current status of trial NCT06541574?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 860 participants. The study started on 2024-03-01. Estimated completion is 2026-06.
What conditions does trial NCT06541574 study?
This clinical trial studies the following conditions: Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy.
What interventions are being tested in trial NCT06541574?
The interventions under investigation include: Methotrexate Injection (DRUG), Methotrexate Infusion (DRUG), Sham Injection (DRUG).
Who is sponsoring clinical trial NCT06541574?
This trial is sponsored by Cincinnati Eye Institute, Southwest Ohio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06541574 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rhegmatogenous Retinal Detachment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR
ACTIVE NOT RECRUITING · Phase 2
-
Dropless Pars Plana Vitrectomy Study
RECRUITING · Phase 4
-
Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.